M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

This trial is testing a new drug called M0324, alone and in combination with pembrolizumab (an immunotherapy drug) or chemotherapy, in people with advanced solid tumors whose cancer overexpresses a protein called MUC-1. MUC-1 is found on many cancer types and M0324 is designed to target it. **You may be eligible if...** - You have an advanced or metastatic solid tumor known to overexpress MUC-1 (such as certain lung, breast, ovarian, or colon cancers) - Your cancer no longer responds to standard treatments, or no standard options exist - For the combination therapy arms: you must have had prior immunotherapy and experienced cancer progression - You are in adequate overall health **You may NOT be eligible if...** - You have not tried standard treatments that are available and appropriate for you - You have active autoimmune disease requiring treatment - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.